Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
about
Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancerNovel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials.Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationshipsBaseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.Design considerations for using PET as a response measure in single site and multicenter clinical trials.Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer.Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness.Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer.Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.A molecular imaging primer: modalities, imaging agents, and applications.Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.Challenges in diagnosis of pancreatic cancer.
P2860
Q26827392-3EC9AEBD-A6BE-4713-A6C0-879E46764606Q30235129-841624BF-E93F-4436-B9E7-573EA66AF756Q33775311-3AD39FD2-1B1A-491B-A0A3-FB5820F0430EQ34072096-347E3E84-512E-4DAF-821D-8E7143504F6BQ34175770-F0C184A7-71EC-4DAF-B5D9-BCA718266714Q35155573-98C4341A-6E94-47AE-B50D-460943CBD7ACQ35213015-7D96DF8E-9D43-4CF7-9903-16EE8B9946ECQ35653277-715AF58C-4A6D-47F8-BCDD-FC1F4A11EB41Q36023889-0520D49E-DD00-4477-AA76-78E9B71CE6B8Q36290046-EC94F77C-4D90-4BDF-9367-3C44E1FF736AQ37259570-5B4786A9-CF14-43B0-84DE-93463F041389Q37395832-C145A08D-A697-4A35-A146-0643CC9A826BQ37738012-57F7F638-1FE5-402A-921B-CE75719F62AFQ37968594-2126D4EE-608D-4C06-A037-F9C581FBFE6BQ38005672-D0573201-A3E5-4AD0-A6DE-19511E42C7F4Q41573034-384CDB39-2019-4EF5-BAE0-F319CB9E9527Q46876969-034AD52A-27E9-4DF2-837B-302E7AEFBFF2Q49391836-C8314132-6BCD-4B71-B65F-18C5443EECA4Q55353877-EDFBCE4E-0CAD-4CE1-AE0E-A2F3FECC5CBD
P2860
Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Using 18F-fluorodeoxyglucose p ...... ly advanced pancreatic cancer.
@en
Using 18F-fluorodeoxyglucose p ...... ly advanced pancreatic cancer.
@nl
type
label
Using 18F-fluorodeoxyglucose p ...... ly advanced pancreatic cancer.
@en
Using 18F-fluorodeoxyglucose p ...... ly advanced pancreatic cancer.
@nl
prefLabel
Using 18F-fluorodeoxyglucose p ...... ly advanced pancreatic cancer.
@en
Using 18F-fluorodeoxyglucose p ...... ly advanced pancreatic cancer.
@nl
P2093
P2860
P1476
Using 18F-fluorodeoxyglucose p ...... ly advanced pancreatic cancer.
@en
P2093
Anthony F Shields
Jawana M Lawhorn-Crews
Lance K Heilbrun
Mark M Zalupski
Minsig Choi
Raghu Venkatramanamoorthy
P2860
P304
P356
10.1097/COC.0B013E3181A76A0B
P577
2010-06-01T00:00:00Z